Form 4: Sonoma Pharmaceuticals CFO Granted 13,500 Restricted Stock Units

Sonoma Pharmaceuticals, Inc.'s Chief Financial Officer, Jerome J. Dvonch, was granted 13,500 restricted stock units, increasing his total beneficial ownership of derivative securities to 25,515 units.

Summary

• Jerome J. Dvonch, Chief Financial Officer of Sonoma Pharmaceuticals, Inc. (SNOA), was granted 13,500 Restricted Stock Units (RSUs) on June 19, 2025.
• Each RSU represents a contingent right to receive one share of common stock.
• The RSUs are scheduled to vest on the third anniversary of the grant date, or upon a change of control.
• This grant was awarded for services performed by Mr. Dvonch.
• Following this transaction, Mr. Dvonch beneficially owns a total of 25,515 derivative securities (RSUs).
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged plan for the acquisition of equity securities.

Sentiment

Score: 7

Explanation: The grant of equity to a key executive like the CFO is generally a positive sign, indicating commitment and aligning interests with shareholders. It's a routine compensation event, not a major strategic announcement, hence a moderate positive score.

Positives

• The grant of Restricted Stock Units to the Chief Financial Officer aligns management's incentives with long-term shareholder value, as the units vest over time and upon specific events.
• The use of a Rule 10b5-1(c) plan indicates a pre-arranged and transparent approach to equity compensation, reducing concerns about opportunistic insider trading.

Risks

• The ultimate value of the granted RSUs to the CFO is directly tied to the future performance and market price of Sonoma Pharmaceuticals' common stock, exposing the compensation to market fluctuations.
• Vesting of the RSUs is contingent on Mr. Dvonch's continued employment for three years or a change of control, introducing a time-based and event-based risk for the recipient.

Future Outlook

The document indicates a future vesting event for the granted Restricted Stock Units on the third anniversary of the grant date (June 19, 2028) or upon a change of control, aligning the CFO's long-term incentives with the company's future performance and strategic direction.

Management Comments

• The RSUs were awarded and granted to Mr. Dvonch for services performed.

Industry Context

This equity grant is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. Such grants are common for aligning management's interests with long-term shareholder value, particularly in companies like Sonoma Pharmaceuticals that may have long development cycles for their products and rely on sustained leadership.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) is a common form of executive compensation across the pharmaceutical and biotech sectors, comparable to practices at companies like Pfizer, Johnson & Johnson, or smaller biotech firms, which frequently use equity to incentivize leadership.
• The vesting schedule, tied to a three-year anniversary or change of control, is a typical long-term incentive structure designed to promote executive retention and focus on sustained company performance, similar to equity plans observed at peer companies.
• The grant price of $0.00 for RSUs is standard, as RSUs represent a contingent right to receive shares, unlike stock options which typically have an exercise price.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CFO's financial interests with the long-term performance and value creation of the company.
• Employees: May signal stability in executive leadership and a commitment to performance-based compensation structures within the company.

Next Steps

• Vesting of 13,500 Restricted Stock Units on June 19, 2028, or upon a change of control.

Key Dates

Recommendation

Keywords

Sonoma Pharmaceuticals, SNOA, Restricted Stock Units, RSU, Equity Compensation, CFO, Jerome Dvonch, SEC Form 4, Insider Transaction, Stock Grant, Corporate Governance